Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Aug 15.

Published in final edited form as: Clin Cancer Res. 2009 Aug 11;15(16):5250–5257. doi: 10.1158/1078-0432.CCR-08-2850

Western blot analysis of biomarkers corresponding to HDAC inhibitor-related proteins (Figure 1, A) and apoptosis-related proteins (Figure 1, B) from CD138+ myeloma cells. Panels A, B, and C display results for baseline and day 11 bone marrow samples following vorinostat-bortezomib therapy in relationship to clinical responses. Numbers reflect densitometric scans of each protein normalized to pre-treatment values, arbitrarily designated as 1.00.

Western blot analysis of biomarkers corresponding to HDAC inhibitor-related proteins (Figure 1, A) and apoptosis-related proteins (Figure 1, B) from CD138+ myeloma cells. Panels A, B, and C display results for baseline and day 11 bone marrow samples following vorinostat-bortezomib therapy in relationship to clinical responses. Numbers reflect densitometric scans of each protein normalized to pre-treatment values, arbitrarily designated as 1.00.